📌 NeoGenomics – USA 🇺🇸

🔍 What is it?

NeoGenomics is a leading provider of oncology-focused real-world data (RWD) derived from clinical genomic testing, pathology, and molecular diagnostics. It offers detailed insights into cancer biomarkers, treatment patterns, and patient outcomes, making it a valuable resource for precision medicine research, drug development, and health economics studies.

-

📊 Key Features & Scope

📍 Geographical coverage: USA 🇺🇸 (nationwide laboratory and genomic testing data)
🏥 Data type: Genomic testing results, pathology reports, molecular diagnostics, oncology-specific clinical data
🕒 Time coverage: Continuously updated, with historical data available
👥 Population covered: Hundreds of thousands of cancer patients tested annually
🔄 Longitudinal data: Available for patients with repeat testing and linked clinical outcomes
📈 Pathologies: Strong focus on oncology, including solid tumors, hematologic malignancies, and rare cancers

✅ Strengths & Best Use Cases

🌍 Comprehensive oncology biomarker data – Includes NGS, FISH, IHC, and cytogenetics results
💊 Precision medicine insights – Supports biomarker-driven research and personalized treatment strategies
📈 Tumor mutation profiling – Enables identification of molecular subtypes and resistance mechanisms
🏥 Real-world oncology trends – Tracks treatment patterns, targeted therapy uptake, and disease progression
🚀 Ideal for oncology RWE, biomarker research, and drug development

-

⚠️ Limitations & Considerations

📉 Limited non-oncology data – Primarily focused on cancer diagnostics
🏥 Lack of full clinical history – Limited integration with full EHR or treatment records beyond diagnostics
🔄 Access to linked patient outcomes may be restricted – Requires additional data linkage for complete longitudinal insights

📚 How to Access & Learn More

🔗 Access: Available through NeoGenomics’ data solutions and research partnerships
🎓 Publications: Link to relevant studies
📄 More info: NeoGenomics Real-World Data Solutions